Back to Clinical Feed
Try:
PLOS ONEResearch HighlightsOpen Access
Early potential safety signals for gliptins and gliflozins using real-world pharmacy data compared to spontaneous reporting
25 Jun 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
- by Maria-Isabel Jimenez-Serrania, Sara-Maria Martinez-Gonzalez, Javier Herradon-Muñoz, Carlos Treceño-Lobato Background Dipeptidyl peptidase 4 inhibitors (DPP4i, gliptins) and sodium-glucose co-transporter 2 inhibitors (SGLT2i, gliflozins) are two oral antidiabetic drug classes that have been widely used in recent decades. Their pharmacological actions have led to the identification of new adverse drug reactions and contraindications.
- In this context, ambulatory real-world data (RWD) analysis has the potential to detect early signals of suspected adverse drug reactions (ADR) that complement or anticipate risk events. Methods We conducted an exploratory pharmacovigilance study based on a multicentre observational cross-sectional survey with retrospective 6-month recall in community pharmacies among patients treated with DPP4i or SGLT2i, using metformin as a control.
- Candidate drug–event signals identified in the pharmacy dataset collected in 2021 were compared with spontaneous reporting data from the Spanish Agency of Medicines and Medical Devices repository in 2022 and 2024. A validated adaptation of the Bayesian Confidence Propagation Neural Network (BCPNN) methodology was applied in all analyses.
Clinical Editorial
Summary
PLOS ONE (Medicine) published a clinical update in Research Highlights on 25 Jun 2026.
The item focuses on Early potential safety signals for gliptins and gliflozins using real-world pharmacy data compared to spontaneous reporting.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.
Related by Condition/Drug
JAHARelated by Drugdapagliflozinempagliflozin
Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial
Cardiology • 14 May 2026
Endocrine NewsRelated by Drugdapagliflozinmetformin
Beyond the Scale: GLP-1 Receptor Agonists and Related Incretin Therapies
Research Highlights • 13 Feb 2026
Endocrine NewsRelated by Drugdapagliflozinmetformin
Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do
Research Highlights • 13 Feb 2026
BMJ OpenRelated by Drugmetformin
Association between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital
Research Highlights • 29 May 2026
NatureRelated by Drugdapagliflozin
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants
Research Highlights • 08 Jun 2026
BMJ OpenRelated by Drugmetformin
LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial
Research Highlights • 22 Apr 2026
Feed Metadata
Source
PLOS ONE (Medicine)
Category
Research Highlights
Published
25 Jun 2026
Feed Metadata
Source
PLOS ONE (Medicine)
Category
Research Highlights
Published
25 Jun 2026